ArticleWorld journal of gastrointestinal surgery2025
MicroRNA 195, lactate dehydrogenase 5, phosphatase and tensin homologue in colorectal cancer: Clinicopathology and prognosis.
Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a prevalent gastrointestinal malignancy, with its pathogenesis involving dysregulation of multiple genes, including adenomatous polyposis coli and p53. Emerging evidence suggests that microRNA 195 (miR195) plays a critical role in carcinogenesis by modulating the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) signaling pathway through phosphatase and tensin homologue (PTEN), thereby influencing cellular metabolism. Loss of PTEN function leads to hyperactivation of PI3K/AKT signaling pathway, resulting in upregulated expression of lactate dehydrogenase-5 (LDH-5) and promoting the tumor progression.
aimTo explore the clinical relevance of miR195, LDH-5, and PTEN expression patterns in CRC patient tissues and their association with clinicopathological features and prognosis.
methodsWe enrolled 53 CRC patients who received surgical resection at our hospital from January 2020 to February 2022. Fresh tumor tissues and paired adjacent normal tissues (> 5 cm from the tumor margin) were collected. The mRNA expression of miR195 was quantified by real-time quantitative polymerase chain reaction, while the protein expression of LDH-5 and PTEN were assessed
resultsThe positive rate of miR195 in CRC tissues (35.85%) was significantly lower than that in adjacent normal tissues (90.57%). LDH-5 displayed a higher positive rate (79.25%) in the tissues compared to normal tissues (11.32%), while PTEN expression was markedly reduced in tumors (28.30%
conclusionLow miR195 and PTEN expression, coupled high LDH-5 expression could constitutes a hallmark molecular signature of CRC progression. These signature may act as potential markers for diagnosis and disease assessment, and prognostic evaluation in CRC patients, eventually improving CRC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.